Oxford, United States
Oxford, United States

Time filter

Source Type

News Article | February 16, 2017
Site: phys.org

Electric cars that require charging and autonomous cars that can be summoned to take you from A to B. How do you take these future challenges into account in spatial planning? And what will Dutch roads and the living environment look like in 2030? In February 2016, the Professional Association of Dutch Architect's Agencies (Branchevereniging Nederlandse Architectenbureaus, BNA) and TU Delft launched a design initiative inviting design teams and the municipalities of Amsterdam, Rotterdam and Utrecht to examine five ring road locations in the respective cities. On Wednesday 15 February 2017, the resulting visions were presented at TU Delft in a new book entitled motorway x City. In order to improve the connection between the city and motorways, and thereby improve liveability, space usage and accessibility, seven multidisciplinary design teams set to work developing visions for five ring road locations: Amsterdam Lelylaan, Amsterdam Gooiseweg, Utrecht Science Park, Rotterdam A20 and Rotterdam A13. Each team included at least one architect, landscape architect, urban planner and traffic expert from various architect's and consultancy agencies. Roads of all types and sizes In parallel with the design team's activities, TU Delft organised a range of education and research activities. These included a research project into the generic aspects of ring roads and the built environment. Hans de Boer, TU Delft Project Manager: 'Fransje Hooimeijer and her colleagues from the Faculty of Architecture and the Built Environment looked at the impact of future types of mobility on five types of ring road: at ground level, raised road, raised road on columns, raised road with ditch and road with ditch. They also examined how these changes would impact the neighbourhoods characterised by the 1950s (reconstruction era), the 1970s ('cauliflower' neighbourhoods, with a tree-like layout) and the 1990s (VINEX neighbourhoods, in large outer city areas). Filip Geerts explored how the road situation will change with the advent of autonomous cars (the line: the cross-section of a motorway). For example, additional space will be created adjacent to roads, because fewer traffic systems will be required. Roberto Cavallo, Valentina Ciccotosto and Manuela Triggianese focused on the space where the motorway and city meet, such as park & rides, in a historical context of technological developments, infrastructure and architecture. In order to develop concrete recommendations for the future, several expert meetings were organised for the design teams and the students involved. The Netherlands Institute for Transport Policy Analysis (KiM) presented a scenario study for self-driving cars. Within TU Delft, Dimitris Milakis from the Faculty of Civil Engineering and Geosciences is studying the potential impact of self-driving cars on road capacity, car ownership and how people choose to travel. The research of Riender Happee, from the Faculty of Mechanical, Maritime and Materials Engineering, focuses on cars that drive autonomously using cameras and sensors, human-machine interaction and the interaction between autonomous vehicles and vulnerable road users. Hans de Boer: 'These academic insights, the expertise of the agencies and the expertise of the involved municipalities and regional branches of Rijkswaterstaat regarding motorways in the urban context all help to accelerate the production of compelling ideas. For example, autonomous cars could be parked under a road raised on columns, while electric cars could be charged at park & ride locations. For example, their use as a traffic junction will intensify as people will be able to switch easily from the autonomous car to the autonomous bus, such as a WEpod'. The study has not only contributed to a vision for the future and a strategy for how to apply this vision, it also resulted in a new working method. Hans de Boer: 'By closely examining the locations together in this way, municipalities and the regional branches of Rijkswaterstaat can identify opportunities to make short-term adjustments, and to include these in maintenance programmes. Consider, for example, improving bicycle access to the residential areas located between the A20 motorway and De Rotte river. By working together, the parties involved will be able to view the motorway in an urban context, and to make optimal use of the space. This is of particular interest to the Ministry of Infrastructure and the Environment, which was also involved in this study. With this book, which is being published in both Dutch and English, we would like to share the acquired insights and working method with other European ministries of infrastructure and the environment (Rijkswaterstaat in Dutch). These ministries have joined forces in the Networking for Urban Vitality joint venture, within which the Dutch Rijkswaterstaat is also an active partner'.


HSINCHU, Taiwan, Mar. 1, 2017 /PRNewswire-FirstCall/ -- ChipMOS TECHNOLOGIES INC. ("ChipMOS" or the "Company") (Taiwan Stock Exchange: 8150 and NASDAQ: IMOS), an industry leading provider of outsourced semiconductor assembly and test services ("OSAT"), today announced that it plans to report financial results for the fourth quarter and full year ended December 31, 2016 after the close of trading on the Taiwan Stock Exchange and before the open of the NASDAQ Stock Market on Thursday, March 9, 2017. The Company's management will host two conference calls to discuss the Company's fourth quarter and full year 2016 financial results, and management's outlook for the first quarter 2017. About ChipMOS TECHNOLOGIES INC.: ChipMOS TECHNOLOGIES INC. ("ChipMOS" or the "Company") (Taiwan Stock Exchange: 8150 and NASDAQ: IMOS) (http://www.chipmos.com) is an industry leading provider of semiconductor assembly and test services. With advanced facilities in Hsinchu Science Park, Hsinchu Industrial Park and Southern Taiwan Science Park in Taiwan, ChipMOS provide assembly and test services to a broad range of customers, including leading fabless semiconductor companies, integrated device manufacturers and independent semiconductor foundries. Forward-Looking Statements This press release contains certain forward-looking statements. These forward-looking statements may be identified by words such as 'believes,' 'expects,' 'anticipates,' 'projects,' 'intends,' 'should,' 'seeks,' 'estimates,' 'future' or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. These statements include financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future operations, products and services, and statements regarding future performance. Actual results may differ materially in the future from those reflected in forward-looking statements contained in this document, due to various factors. These risks and uncertainties include those discussed under "Cautionary Statement Concerning Forward Looking Statements" and "Risk Factors" in the prospectus included in the registration statement on Form F-4 that ChipMOS filed with the U.S. SEC. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/chipmos-to-report-fourth-quarter-and-full-year-2016-financial-results-on-march-9-2017-300415746.html


News Article | February 27, 2017
Site: globenewswire.com

LEIDEN, the Netherlands, Feb. 27, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases including cystic fibrosis (CF), Leber's congenital amaurosis Type 10 (LCA 10) and dystrophic epidermolysis bullosa (DEB), today announced its support of Rare Disease Day, joining rare disease patients and families, patient organizations and health care providers to raise awareness of rare diseases. Together with members of the rare disease community, ProQR is proud to participate at a Rare Disease Day Lunch Symposium, organized by Leiden Bio Science Park Foundation (NL) to highlight the importance of research in rare diseases and recognize the crucial role that patients play in it. Every last day of February, Rare Disease Day is an international awareness campaign led by the patient organization EURORDIS and supported by hundreds of other patient organizations around the world. February 28, 2017 marks the tenth Rare Disease Day and this year’s slogan 'With research, possibilities are limitless’ underlines the hope that research brings to the millions of people living with a rare disease around the world and their families. “It is our mission to make a meaningful impact on the lives of patients that suffer from severe genetic rare diseases and therefore we are honored to be part of this event on Rare Disease Day to raise awareness and emphasize the importance of research,” said Daniel A. de Boer, Chief Executive Officer of ProQR. “Together with our partners at the Leiden Bio Science Park and many others around the world we are inspired by the stories of people affected by rare diseases and hope many more will join us in our quest to find treatments for all of them.” CF is the most common fatal inherited disease in the Western world and affects an estimated 65,000 patients worldwide. In people with CF, a defective CFTR gene causes a thick, buildup of mucus in the lungs, pancreas and other organs. In the lungs, the mucus clogs the airways and traps bacteria leading to infections, extensive lung damage and eventually, respiratory failure. There is no cure for CF. Disease manifestations lead to a shortened life expectancy with a median age of death of 27 years. Although over 1,900 CF-causing gene mutations have been identified, approximately 70% of all CF patients are affected by the F508del mutation. Among all CF patients, approximately 50% are homozygous for the F508del mutation. Leber’s congenital amaurosis is the most common cause of blindness in children and consists of a group of diseases of which LCA Type 10 (LCA 10) is one of the more severe forms. LCA 10 leads to progressive loss of vision causing most patients to lose their sight in the first few years of life. To date, there are no treatments approved or products in clinical development that treat the underlying cause of the disease. LCA 10 is caused by mutations in the CEP290 gene of which the p.Cys998X mutation is most common. Although prevalence rates vary, we believe approximately 2,000 people in the Western world have LCA 10 because of this mutation. Dystrophic epidermolysis bullosa (DEB) is a rare blistering disorder of the skin and mucosal membranes and is characterized by extremely fragile skin that blisters and tears from minor friction or trauma leaving poorly healing wounds. DEB is painful and debilitating and is associated with very low quality of life and limited life expectancy. The disease is caused by mutations in the COL7A1 gene that lead to a very weak connection between the dermis (inner layer) and the epidermis (outer layer) in the skin. Approximately 2,000 patients have DEB because of mutations in exon 73 of the COL7A1 gene. There is currently no treatment available. This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to”, “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. Forward-looking statements are based on management’s beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, statements regarding Rare Disease Day and our mission to pursue treatments for rare diseases. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with our clinical development activities, manufacturing processes and facilities, regulatory oversight, product commercialization, intellectual property claims, and the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including certain sections of our annual report filed on Form 20-F. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.


News Article | February 15, 2017
Site: www.marketwired.com

Offering over 40 Percent Better DMIPS/mW Performance Efficiency, Andes Technology Corporation's N8 Beat Competitive Alternative to Win the Multiple Designs HSINCHU, TAIWAN--(Marketwired - February 15, 2017) - Andes Technology Corporation, the leading Asia-based supplier of small, low-power, high performance 32-bit embedded CPU cores, today announced that Wuxi China Resources Semico Co., Ltd. selected the Andes ultra-low power, high performance N8 CPU core over a major competitor for multiple design sockets: one for a touch controller SoC and a second for smart home appliances SoC. The Andes N8 won the design by outperforming the rival core, offering over 40 percent better DMIPS/mW performance efficiency. Both SoCs are shipping in high volume to Wuxi China Resources customers worldwide. "We are extremely pleased that Wuxi China Resources Semico Co., Ltd. chose our N8 core for their high volume SoC designs," said Charlie Hong-Men Su CTO and Senior Vice President of R&D and Technical Marketing. "Wuxi China Resources Semico Co., Ltd. is one of China's top 10 integrated circuit design enterprises with a distinguished group of designers having a breadth of experience and expertise, first-class IC design tools, and testing facilities. This has enabled the company to be counted among China's top 50 semiconductor companies as reported in PriceWaterhouseCoopers' "China's impact on the semiconductor industry 2014 update." "We are pleased to have Andes Technology Corp. as our CPU core supplier," said Zhao Jian-Kun, General Manager of Wuxi China Resources Semico Co., Ltd. "They have been a supportive and reliable supplier for a number of SoC designs. Our company does business in a highly competitive international market. Having Andes Cores providing our chips a power and performance advantage affords our products an edge in the market for touch controller and smart home appliances SoCs. We look forward to a continuing relationship with Andes." The AndesCore™ N8 targets microcontroller applications and features the latest AndeStar™ V3m instruction set architecture (ISA). The ISA enables optimal performance in a low power budget and small code size. The ISA intermixes 32-bit and 16-bit instructions, such as compare-and-branch on immediate, load/store with increment, and shift-and-ALU. With its 3-stage pipeline design, the N8 core boosts the execution efficiency of today's computation algorithms, reduces memory usage, lowers customers' silicon cost, while providing a long-term roadmap for customers needing an upgrade path from 8-bit cores. It offers vectored interrupt for low latency interrupt processing, a small footprint with low gate count and high code density, and FlashFetch technology, which speeds up flash memory accesses while reducing overall power consumption. About Wuxi China Resources Semico Co., Ltd. Wuxi China Resources Semico Co., Ltd., one of the leading PRC fabless design houses in terms of technology and scale. The company's expertise in digital and mixed-signal technologies enables the design and development of semiconductor products such as SoCs for touch control in portable devices as well as MCU and audio and video processing SoCs in smart home appliances and consumer electronics such as television, Hi-Fi, DVD and MP3 players, game consoles, telecommunication devices, voice synthesizers, etc. Andes Technology Corporation was founded in Hsinchu Science Park, Taiwan in 2005 to develop innovative high-performance/low-power 32-bit processor cores and associated development environment to serve worldwide rapidly growing embedded system applications. The company delivers the best super low power CPU cores with integrated development environment and associated software and hardware solutions for efficient SoC design. To meet the demanding requirements of today's electronic devices, Andes Technology delivers configurable software/hardware IP and scalable platforms to respond to customers' needs for quality products and faster time-to-market. Andes Technology's comprehensive CPU includes entry-level, mid-range, high-end, extensible and security families to address the full range of embedded electronics products, especially for connected, smart and green applications. For more information about Andes Technology, please visit http://www.andestech.com/.


News Article | February 28, 2017
Site: www.prweb.com

C2G Partners, a marketing and analytics consulting company based in New Jersey, announces that it is changing its name from Consultants 2 Go® LLC. Their new name, C2G Partners, demonstrates their commitment to their customers and their growth strategy to expand their network and breadth of offerings. At their core, C2G Partners is still the same company, with the same values they have had since their founding in 2002, now with a more focused name and better capabilities. C2G Partners has the same leadership, experience and ongoing mission to profitably grow their clients’ businesses through expert marketing resources. Patrick Hennessy, CEO and President of C2G Partners said, “Sandi and Peggy have built an impressive company with strong, sustained growth for many years. We are excited about integrating our talents in the analytics and digital technology space to further enhance C2G Partners’ excellent marketing consultancy. This sets the foundation for a much bigger platform through organic growth and more strategic acquisitions.” C2G Partners provides marketing and analytics consultants to Fortune 500 and other industry leading companies, specializing in the financial services and telecom industries. C2G Partners has a deep bench of highly-qualified consultants that have a proven record of solving marketing challenges and delivering immediate results for their clients. C2G Partners has evolved from a small startup to a successful marketing and analytics solutions company, being ranked among Inc. Magazine’s “Inc. 500 | 5000” list of the fastest growing companies in America, five out of the last six years. C2G Partners reflects what they have become as a company and their aspirations—to be the preeminent provider of data driven marketing solutions in the industry. Peggy McHale, Managing Director of C2G Partners, said, “Our expanding digital expertise and the launch of our Data Science practice will bolster our offerings in the marketplace. This will allow us to address our clients’ needs by providing capabilities that keep them at the forefront of their industries with breakthrough solutions.” C2G Partners is led by co-founders Sandi Webster and Peggy McHale, executives in the field of marketing and analytics for Fortune 500 companies. In 2016, Patrick Hennessy, Jean Holder and Ozgur Dogan joined the C2G Partners’ executive leadership team, bringing with them years of leadership experience in the analytics, digital and CRM industries. Together, they are further expanding C2G Partners’ talent pool, capabilities, and solutions to help their clients drive success in the marketplace. “Our leadership, talent and expertise provide C2G Partners with an exciting opportunity to deliver even greater value to our clients while driving new growth. We are positioned to continually build the best network of consulting talent and extend relationships with industry partners,” stated Sandi Webster, Managing Director of C2G Partners. For more information, please visit the websites for C2G Partners and Whitegate Capital Partners. About C2G Partners C2G Partners is a leading marketing and analytics consulting company headquartered at University Science Park, 105 Lock Street, Suite 309, Newark, NJ, 07103. C2G Partners provides marketing and analytics consultants to Fortune 500 and other industry leading companies, specializing in the financial services and telecom industries. C2G Partners holds memberships in The American Marketing Association, NJ Tech Council, The Brooklyn and Manhattan Chambers of Commerce, National Association of Women Business Owners, National Association for Female Executives, Women Presidents' Organization, and C200. For more information, contact us at info(at)C2GPartners(dot)com or go to c2gpartners.com.


News Article | February 27, 2017
Site: globenewswire.com

REHOVOT, Israel, Feb. 27, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that CEO Oded S. Lieberman, PhD will present at the following investor conferences: To access the live webcast of the presentation, please visit ir.neuroderm.com/.  A replay will be available for a limited time following the presentation. About NeuroDerm NeuroDerm is a clinical-stage pharmaceutical company developing central nervous system (CNS) product candidates that are designed to overcome major deficiencies of current treatments and achieve enhanced clinical efficacy through continuous, controlled administration. NeuroDerm is headquartered in the Rabin Science Park, Rehovot, Israel.


SINGAPORE, Feb. 28, 2017 /PRNewswire/ -- Spacemob, the Vertex Ventures backed coworking space operator, today announced a strategic partnership with Ascendas-Singbridge -- Asia's leading provider of sustainable urban and business space solutions -- to open a coworking space in Singapore Science Park at the end of March 2017. The 14,000 sq ft space at Ascent, a new Ascendas-Singbridge development located opposite Kent Ridge MRT Station at Singapore Science Park 1, will provide small businesses with cost-effective spaces, close proximity to key research and tertiary institutions, R&D, high-tech innovation and start-up communities. Ascendas-Singbridge Group CEO, Mr Miguel Ko says; "We are delighted to partner with Spacemob to provide coworking spaces to entrepreneurs and small-medium businesses in the thriving ecosystem at Singapore Science Park. With their track record in attracting members, community building, and integration of technology into coworking, Spacemob stands out as a key player in this rapidly emerging market." Spacemob Founder and CEO, Turochas "T" Fuad has a track record of disrupting industries to unlock sources of growth. Spacemob forms partnerships with property owners to operate coworking spaces and generate new revenue streams for them. With their first space at Claymore Hill in Orchard, they are also one of the first major coworking players located outside the CBD. He says; "We are delighted to be working with Ascendas-Singbridge on our second coworking space in Singapore. One of our objectives as a company is to enable space as a service and maximise space usage for our property partners. This will allow us to house a hundred companies and expand our coworking community at a convenient and accessible location. We look forward to growing across the region with similar partnerships and offerings." Spacemob at Ascent offers members state-of-the-art facilities such as ergonomic chairs, adjustable desks, complimentary group health insurance, payroll software, media rooms, and a host of Spacemob signature tools and technology that a business needs to thrive. By moving closer to city fringe areas, Spacemob is executing on its mission for space to follow its members. Spacemob is poised for further growth in 2017 with coworking spaces coming to Jakarta, Thailand and Vietnam. Spacemob launched its first site on Claymore Hill in October 2016. In November 2016, the company announced SGD7.9million seed funding led by Vertex Ventures. Recently voted 3rd 'Hottest Startups 2017' by Singapore Business Review, Spacemob is founded by Turochas 'T' Fuad (founder of Travelmob, the short-term rental site that was acquired by HomeAway in 2013). Spacemob develops proprietary technology to benefit members. The Claymore Hill site currently has entrepreneurs, freelancers and MNCs such as General Assembly and Big Sync (a Unilever company) as its members. Another one Spacemob site is due to open in Q1 of 2017 in Jakarta. The plan is to have 30 Spacemob sites across Asia Pacific within the next 36 months. Ascendas-Singbridge Group is Asia's leading sustainable urban and business space solutions provider. With the combined capabilities of Ascendas and Singbridge, the group is uniquely placed to undertake urbanisation projects spanning townships, mixed-use developments and business/industrial parks. Headquartered in Singapore, Ascendas-Singbridge has projects in 29 cities across 10 countries in Asia, including Australia, China, India, Indonesia, Singapore and South Korea. Ascendas-Singbridge Group has a substantial interest in and also manages three Singapore-listed funds under its subsidiary Ascendas. Besides these listed funds -- Ascendas Reit, Ascendas India Trust and Ascendas Hospitality Trust, Ascendas also manages a series of private real estate funds, which hold commercial and industrial assets across Asia. Jointly owned by Temasek and JTC Corporation (JTC) through a 51:49 partnership, Ascendas-Singbridge Group is the asset and investment holding arm of the integrated urban solutions platform formed by Temasek and JTC to capitalise on urbanisation trends in the region. Strategically located at the gateway of Singapore Science Park 1, Ascent is a          7-storey integrated development offering approximately 40,000 sqm of business park space, with 4,000 sqm for retail and food and beverage outlets.  A short 5-minute walk to the Kent Ridge MRT station, Ascent offers accessibility as well as efficiency of space with large, contiguous floor plates of up to 7,000 sqm. The iconic development redefines Singapore Science Park with human-centric architecture, and lush landscaping throughout the grounds.


- Trial 006 demonstrated a statistically significant and clinically meaningful reduction in OFF-time and increase in proportion of patients “ON” by 8:00 am (primary and key secondary endpoints) - - The trial also showed statistically significant reduction in troublesome dyskinesia and a complete reduction of OFF-time to zero hours in 66% of responders (post hoc sub-groups analyses) - - Company to host conference call and webcast today at 8:30 a.m. ET- REHOVOT, Israel, March 01, 2017 (GLOBE NEWSWIRE) --  NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS) disorders, today announced that a preliminary analysis of trial 006 demonstrated that the trial successfully met its primary, key secondary and additional secondary endpoints. Trial 006 was an international open label, blinded rater, phase II study of ND0612H, NeuroDerm's high dose continuous, subcutaneously delivered levodopa/carbidopa (LD/CD) liquid formulation, in patients with advanced Parkinson's disease. NeuroDerm also announced that it has modified its EU clinical and regulatory development strategy following a meeting with the European Medicines Agency (EMA). The modified strategy will be based on NeuroDerm's restarted and amended iNDiGO phase III efficacy study (trial 007), rather than on bioequivalent pharmacokinetic (PK) studies. Based on discussions with the EMA, NeuroDerm believes that this strategy should allow it to pursue a broader EU label, with no effect on its clinical and regulatory timelines. “The very prominent responder effect, as well as the significant reductions in OFF-time and troublesome dyskinesia observed in trial 006, are extremely encouraging and demonstrate the substantial potential for ND0612 to make a meaningful difference in the lives of patients living with Parkinson’s disease,” said Oded S. Lieberman, PhD, CEO of NeuroDerm.  “We believe that restarting and amending the iNDiGO trial, incorporating both an ND0612H arm and new endpoints that reflect these very positive preliminary results from trial 006, should support a broader label in the EU and increase the clinical and commercial potential of ND0612 while not affecting our clinical timelines.  We are committed to improving the lives of Parkinson's patients by achieving our clinical and regulatory objectives as quickly as possible and providing Parkinson’s disease patients with a safer and more effective alternative to current treatment options.” Trial 006 Endpoints The primary endpoint of this study was to assess the change from baseline to day 28 in daily OFF-time (normalized to 16 waking hours) as assessed by a blinded rater.  A key secondary endpoint was to assess the percentage of subjects who were “ON” by 8:00am and 9:00am. Additional secondary endpoints were also evaluated as well as safety and tolerability. Trial 006 Design Trial 006 was a 28-day multicenter, international (US, EU and Israel), parallel-group, blinded rater, randomized phase II study that investigated the efficacy, safety, tolerability and pharmacokinetics of two dosing regimens (R1 and R2) of ND0612H and compared them to the baseline of standard optimized oral therapy: All patients could add oral LD/CD therapy at any time as needed.  The trial enrolled 38 patients with advanced Parkinson’s disease. Trial 006 Preliminary Results The 38 enrolled subjects had typical characteristics for patients with advanced Parkinson’s disease including: an average age of 63.5 years, 11.5 years since diagnosis and an average baseline OFF-time of 5.3 hours per day. OFF-time (primary endpoint): The primary endpoint was met in R1. From 5.5 hours at baseline, the OFF-time was reduced by 2.8 hours (p equals 0.004). There was a smaller, non-statistically significant reduction of 1.3 hours in OFF-time in R2. “ON” by 8:00am and 9:00am (key secondary endpoint): In R1, the proportion of patients who achieved the first “ON” by 8:00am (as reported by the patient) increased from 11% at baseline to 50% by day 28 (p equals 0.020), and, by 9:00am, from 26% at baseline to 75% (p equals 0.004). In R2, dosing began in the morning and there was therefore no improvement from baseline at either timepoint. Complete reduction of OFF-time (post-hoc analysis): In R1, 42% of patients had a complete reduction in OFF-time to zero hours (in R2, 11% experienced complete resolution of OFF-time). Patients who experienced reduction in OFF-time (greater than 0 hours change) during the trial were defined as “Responders” and constituted 68% of all patients (12 patients in R1 and 14 patients in R2). Eight (66%) of the Responders in R1 (and two (14%) of the Responders in R2) experienced a complete reduction of their OFF-time to zero hours; all Responders in R1 experienced a reduction of more than 50% in their OFF-time. “Good” ON  (secondary endpoint): Good ON (defined as “ON” with no or mild dyskinesia, as assessed by the blinded rater) increased in R1 from 9.2 hours by 3.7 hours (p less than 0.001), and in R2 from 8.5 hours by 2.8 hours (p equals 0.003). Unified Parkinson’s Disease Rating Scale (UPDRS) III by 8:00am (post-hoc analysis): UPDRS III score by 8:00am decreased in R1 from 37.4 at baseline by 19.1 points (p less than 0.001) and from 37.3 at baseline by 10.7 points in R2 (p equals 0.001). Troublesome Dyskinesia (post hoc analysis): Troublesome dyskinesia (defined as “ON” with moderate or severe dyskinesia as assessed by the blinded rater) decreased from 5.1 hours at baseline by 3.5 hours (p equals 0.011) in the subgroup of all patients who had at least 1 hour of troublesome dyskinesia at baseline (N equals 14, R1 and R2 combined). Oral LD Dosing and Frequency (post hoc analysis): Average dosing frequency of oral levodopa decreased in all patients from 6.6 times at baseline to 2.3 times per day by day 28. The average dose of oral LD decreased from approximately1100mg at baseline to approximately 330mg. Safety and Tolerability: 33 subjects (87%) out of 38 completed the study with 5 who did not complete the study, two of which were due to adverse events: one due to an infection at the infusion site and the other due to worsening of symptoms. Infusion site reactions (nodules, bruising and erythema) were common yet generally well tolerated. These results corroborate the safety and tolerability data obtained in previous studies and did not raise new safety or tolerability concerns. Preliminary Results: Preliminary trial 006 results demonstrate that the R1 dosing regimen provides a significant reduction in OFF-time and a significant increase in ON-time with no or mild dyskinesia. A substantial percentage of subjects experienced complete resolution of OFF-time. The treatment was associated with some nodules, consistent with prior trials, but otherwise did not raise new safety or tolerability concerns. Benefits were also seen with the R2 regimen in spite of the study design whereby patients started levodopa therapy later in the morning.  ND0612H devices were generally found to be reliable with only few minor, correctable malfunctions reported. No inconvenience related to the wearing of the device was reported for either day or night administration. Detailed trial results will be presented at a future medical meeting. ND0612 EU Clinical and Regulatory Development NeuroDerm recently received minutes from a meeting held in January 2017 with the EMA's Scientific Advice Working Party.  Based on this meeting and on the preliminary results of trial 006, NeuroDerm has modified its EU clinical and regulatory development path. Upon completion of its ongoing trials, NeuroDerm plans to submit a marketing application based on the results of an amended iNDiGO phase III efficacy study and the ongoing BeyoND (trial 012) long-term safety trial, seeking to obtain a broader label for ND0612 than the label that could have been granted under a PK regulatory route in the EU.  The previously planned PK trial (trial 009) will not be carried out.  Anticipated timelines for submission of the EU marketing application remain unchanged. NeuroDerm's U.S. clinical and regulatory development timelines also remain unchanged. iNDiGO Trial NeuroDerm's iNDiGO phase III efficacy study (trial 007) will be restarted and amended to support a broad label claim in the EU for ND0612. The trial will be expanded from 150 to 240 patients by adding a third treatment arm of ND0612H to the current ND0612L and control arms. Furthermore, new endpoints that reflect the recent trial 006 results, including a responder analysis, will be incorporated into this trial. NeuroDerm believes that these should enable the company to seek approval for both the low- and high-dose versions of ND0612 in the EU.  It is anticipated that iNDiGO will be completed in 2018, in parallel to the ongoing long term BeyoND safety trial (Trial 012). Conference Call Details NeuroDerm will host a conference call at 8:30 a.m. ET today.  Individuals can access the webcast in the Events and Presentations section of the Company’s website, by clicking here, or by dialing 844-452-2810 (U.S.) or 574-990-9831 (outside of the U.S.).  The passcode is 79280228.  A webcast will be archived on the website. About ND0612 ND0612 is designed to significantly reduce motor complications in Parkinson's disease patients through continuous, subcutaneous delivery of LD/CD solution. Previously completed Phase II trials demonstrated that the low dose ND0612L maintained steady, therapeutic levodopa plasma concentrations that were associated with major changes in several clinical parameters including “OFF” time reductions when added to optimal oral standard of care. The high dose ND0612H, intended for severe Parkinson’s disease patients, was shown to reach even higher levodopa steady plasma levels, indicating that it may provide an effective therapy alternative to current treatments requiring surgery such as deep brain stimulation and LD/CD Intestinal Gel. About Parkinson's disease Parkinson's disease is a progressive neurodegenerative illness characterized by reduced dopamine in the brain, resulting in a debilitating decrease in the patient's motor and non-motor functions. Its symptoms, such as trembling in the extremities and face, slowness of movement and impaired balance and coordination, worsen over time and gravely impact the patient's quality of life. Levodopa is the most effective treatment for Parkinson’s disease. However, chronic oral levodopa treatment is associated with fluctuations in motor response as result of which, despite the benefits of the drug, patients can experience periods of impaired motor and non-motor functions, also referred to as “OFF” time. In addition, mainly as a result of excessive/intermittent oral doses of levodopa aimed at treating the “OFF” time, some patients experience involuntary movements, or dyskinesia. The “OFF” time and dyskinesia affect the majority of levodopa-treated Parkinson's disease patients and can interfere with day-to-day functions, causing patients to become severely disabled. Current evidence suggests that intermittent dosing with standard oral formulations of levodopa contributes to the development of these motor complications. By contrast, it has been shown that continuous administration of levodopa can effectively treat motor fluctuations in Parkinson's disease patients without increasing troublesome dyskinesia; however, a convenient route for continuous administration has not been introduced to date. About NeuroDerm NeuroDerm is a clinical-stage pharmaceutical company developing drug-device combinations for central nervous system (CNS) disorders that are designed to overcome major deficiencies of current treatments and achieve enhanced clinical efficacy through continuous, controlled administration. NeuroDerm has three product candidates in different stages of development which offer a solution for almost every Parkinson’s disease patient from the moderate to the very severe stage of the disease. NeuroDerm has developed a line of levodopa and carbidopa (LD/CD) product candidates administered through small belt pumps that deliver a continuous, controlled dose of LD/CD. The LD/CD product candidates are ND0612L and ND0612H, which are used for treatment of moderate and advanced Parkinson’s disease patients, respectively, and which are delivered subcutaneously. In addition, NeuroDerm is developing ND0701, a novel subcutaneously delivered apomorphine formulation for patients who suffer from moderate to severe Parkinson’s disease and who do not respond well to LD/CD. NeuroDerm is headquartered in the Weizmann Science Park in Rehovot, Israel. Forward-Looking Statements This press release contains forward-looking statements, within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended that involve risks and uncertainties. Such forward-looking statements may include projections regarding our future performance and may be identified by words like "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "future," "will," "seek" and similar terms or phrases. The forward-looking statements contained in this press release are based on management's current expectations and projections about future events. There are important factors that could cause our actual results, levels of activity, performance or achievements to differ materially from the results, levels of activity, performance or achievements expressed or implied by the forward-looking statements. In particular, you should consider the risks provided under "Risk Factors" in our annual report on Form 20-F for the year ended December 31, 2015 filed with the Securities and Exchange Commission. Any forward-looking statement made by us in this press release speaks only as of the date hereof. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.


News Article | February 27, 2017
Site: www.businesswire.com

AMSTERDAM--(BUSINESS WIRE)--Interxion Holding NV (NYSE:INXN), (“Interxion”), a leading European provider of carrier and cloud-neutral colocation data centre services, announced today that it has acquired a data centre business from Vancis Holding BV, a leading independent Dutch provider of colocation, cloud & managed services based in Amsterdam’s Science Park. The acquired data centre business is located in the connectivity heart of Amsterdam. As the location where the Amsterdam Internet Exchange was first established, it houses a rich and diverse community of connectivity providers. This Science Park asset, which has access to more than 100 carriers and ISPs, doubles Interxion’s existing carrier density in Amsterdam and will enable customers across the metro area to interconnect at low latency and low cost. Customers in both Interxion’s Schiphol and Science Park campuses can now easily access the robust connectivity options across the two campuses, including all the top international carriers, over 40 ISPs, all major internet exchanges, as well as the world’s leading cloud platforms. “Global businesses today require access to dense connectivity and multiple cloud platforms in order to meet the dynamic requirements of their customers and to drive value,” said David Ruberg, Interxion Chief Executive Officer. “Interxion Science Park extends our campus into another dimension of Amsterdam’s connectivity community and enhances the value proposition of our Schiphol campus by doubling our carrier and ISP density in one of Europe’s primary colocation markets.” The acquired data centre, which is now designated as “Interxion Science Park,” is a key connectivity hub for customers that serve The Netherlands and Western Europe. Approximately 75% of its 1,800 sqm of equipped space is utilised, and it has 2.5 MW of customer available power. In addition, Interxion has identified options to expand the capacity at the current Science Park facilities. Vancis C&MS BV will continue to own and operate its existing Cloud and Managed Services business and has entered into a strategic partnership with Interxion to continue servicing its customers. Interxion (NYSE:INXN) is a leading provider of carrier and cloud-neutral colocation data centre services in Europe, serving a wide range of customers through 45 data centres in 11 European countries. Interxion’s uniformly designed, energy-efficient data centres offer customers extensive security and uptime for their mission-critical applications. With over 600 connectivity providers, 21 European Internet exchanges, and most leading cloud and digital media platforms across its footprint, Interxion has created connectivity, cloud, content and finance hubs that foster growing customer communities of interest. For more information, please visit www.interxion.com. Vancis C&MS is a leading independent integrated cloud & managed services company servicing a broad customer base in the Netherlands with a strong foothold in the Educational, Research and Health Care industries. With over 100 employees, Vancis C&MS offers integrated high-availability mission-critical hosting and managed services solutions, building upon their flexible and scalable hosting infrastructure, with end-to-end customer solutions driven by in-depth industry knowledge. For more information, please visit www.vancis.nl. This communication contains forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such forward-looking statements. Factors that could cause actual results and future events to differ materially from Interxion’s expectations include, but are not limited to, the ability to integrate the acquisition, the difficulty of reducing operating expenses in the short term, the inability to utilise the capacity of newly planned data centres and data centre expansions, significant competition, the cost and supply of electrical power, data centre industry over-capacity, performance under service level agreements, certain other risks detailed herein and other risks described from time to time in Interxion’s filings with the United States Securities and Exchange Commission (the “SEC”). Interxion does not assume any obligation to update the forward-looking information contained in this report.


News Article | February 15, 2017
Site: www.marketwired.com

NESS-ZIONA, ISRAEL and TORONTO, ON--(Marketwired - February 09, 2017) - Vaxil Bio Ltd. ("Vaxil", or the "Company") (TSX VENTURE: VXL) today announces its participation in the Annual BIO CEO and Investor Conference. Vaxil's Dr. Limor Chen will present an overview of the Company's R&D and clinical strategy in regard to its immunotherapy products. Now in its 19th year, the BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies. A copy of the presentation will be made available on Vaxil's website via the Company's Investor Center or by clicking here: http://vxlbio.com/investor-center/investor-presentations/ Immucin™ -- Orphan Drug Designated Immunotherapy Immucin™ is thought to target antigens via novel mechanism acting as a neo-antigen. Vaxil has recently begun testing combination options with data suggesting potentially complimentary synergies with checkpoint inhibitors and IMiDs. Phase-I/II successfully completed, with Orphan Drug Designation, Vaxil is currently planning for a larger Phase-II. SPmAb™ -- First-ever Signal Peptide Specific Antibodies Antibody platform believed to be more targeted and specific against antigens specific to tumor cells while simultaneously avoiding soluble antigens found in normal cells. MTbuVax™ -- Patented Anti-Infective Vaccine Superior immunity demonstrated in tuberculosis patient samples vs current vaccines, strong and specific cellular responses, recently granted US Patent. About Vaxil Vaxil is a cutting edge Israeli-Canadian immunotherapy focused biotech with its R&D based in the Weizmann Science Park, Israel and listed on the TSX-Venture. Vaxil specializes in the development of immunotherapy products for the treatment of cancer and infectious diseases by activating the patient's own immune system, including nearly 10 years of R&D and a robust patent portfolio. Vaxil immunotherapy products are based on its VaxHit™ platform, a proprietary algorithm for identifying, isolating, and producing signal peptide specific immunotherapy products believed to target prominent markers via novel mechanism. The first product developed through VaxHit™ is known as ImMucin™, a therapeutic cancer vaccine, which received Orphan Drug Designation from both FDA and EMA. ImMucin™ was generated to target the signal peptide of MUC1, a prominent antigen found in 90% of cancers yet to date unresponsive to other therapies. Vaxil believes Immucin™ acts via novel mechanism as a neo-antigen. Recently, Vaxil has shown that ImMucin™ can potentially elicit a strong anti-tumor activity when used in combination with checkpoint inhibitors. In a Phase-I/II, 100% of patients demonstrated robust immune responses, with the majority of patients achieving stable disease, and the Company is now planning for a larger Phase-II. Vaxil's antibody platform, known as SPmAb™, are the first-ever signal peptide specific antibodies. The Company believes its antibodies possess several key advantages, including the targeting of cancer at its earliest stages. To date, SPmAbs™ have been shown to induce anti-tumor activity in mouse cancer models. In addition to oncology, Vaxil has developed and patented MTbuVax™, a novel TB vaccine, which has demonstrated superior immunity when compared to currently available vaccines. Vaxil believes the field of infectious diseases to be particularly important given the rise of super-bugs, antibiotic resistant strains of infections, including the World Health Organization reporting a rise in people developing multi-drug resistance to tuberculosis. To date, Vaxil has demonstrated both in human samples, as well as in mice, that its various MTbuVax™ candidates have potential to elicit stronger, more specific immune responses. Disclaimer: The TSX Venture Exchange Inc. has in no way passed upon the merits of the Company has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including the availability of funds, the results of financing efforts, the results of exploration activities -- that could cause actual results to differ materially from the Company's expectations are disclosed in the Company's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This press release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities described herein in the United States or elsewhere. These securities have not been, and will not be, registered in the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States or to U.S. persons unless registered or exempt therefrom.

Loading Science Park collaborators
Loading Science Park collaborators